Abstract:Cardiovascular (CV) disease is the leading cause of death in dialysis patients and is strongly associated with fluid overload and hypertension. It is plausible that low dialysate sodium ion concentration [Na+] may decrease total body sodium content, thereby reducing fluid overload and hypertension and ultimately reducing CV morbidity and death. This is an update of a review first published in 2019. This review evaluated the harms and benefits of using a low (< 138 mM) dialysate [Na+] for maintenance haemodialysis (HD) patients. We searched the Cochrane Kidney and Transplant Register of Studies up to 1 October 2024 through contact with the Information Specialist using search terms relevant to this review. Studies in the Register are identified through searches of CENTRAL, MEDLINE, and EMBASE, conference proceedings, the International Clinical Trials Registry Platform (ICTRP) Search Portal and ClinicalTrials.gov. Randomised controlled trials (RCTs), both parallel and cross‐over, of low ( 140 mM) dialysate [Na+] for maintenance HD patients were included. Two authors independently screened studies for inclusion and extracted data. Statistical analyses were performed using the random‐effects model, and results expressed as risk ratios (RR) for dichotomous outcomes, and mean differences (MD) or standardised MD (SMD) for continuous outcomes, with 95% confidence intervals (CI). Confidence in the evidence was assessed using Grades of Recommendation, Assessment, Development and Evaluation (GRADE). We included 17 studies randomising 509 patients, with data available for 452 patients after dropouts. All but three studies evaluated a fixed concentration of low dialysate [Na+], with one using profiled dialysate [Na+] and two using individualised dialysate [Na+]. Five were parallel group studies, and 12 were cross‐over studies. Of the latter, only six used a washout between intervention and control periods. Most studies were short‐term with a median (interquartile range) follow‐up of 4 (4 to 16) weeks. Two were of a single HD session and two of a single week's HD. Seven studies were conducted prior to 2000, and six reported the use of obsolete HD practices. Other than for indirectness arising from older studies, risks of bias in the included studies were generally low. Compared to neutral or high dialysate [Na+] (≥ 138 mM), low dialysate [Na+] (< 138 mM) reduces interdialytic weight gain (14 studies, 515 participants: MD ‐0.36 kg, 95% CI ‐0.50 to ‐0.22; high certainty evidence) and antihypertensive medication use (5 studies, 241 participants: SMD ‐0.37, 95% CI ‐0.64 to ‐0.1; high certainty evidence), and probably reduces left ventricular mass index (2 studies, 143 participants: MD ‐7.65 g/m 2 , 95% CI ‐14.48 to ‐0.83; moderate certainty evidence), predialysis mean arterial pressure (MAP) (5 studies, 232 participants: MD ‐3.39 mm Hg, 95% CI ‐5.17 to ‐1.61; moderate certainty evidence), postdialysis MAP (5 studies, 226 participants: MD ‐3.17 mm Hg, 95% CI ‐4.68 to 1.67; moderate certainty evidence), predialysis serum [Na+] (11 studies, 435 participants: MD ‐1.26 mM, 95% CI ‐1.81 to ‐0.72; moderate certainty evidence) and postdialysis serum [Na+] (6 studies, 188 participants: MD ‐3.09 mM, 95% CI ‐4.29 to ‐1.88; moderate certainty evidence). Compared to neutral or high dialysate [Na+], low dialysate [Na+] probably increases intradialytic hypotension events (13 studies, 15,764 HD sessions: RR 1.58, 95% 1.25 to 2.01; moderate certainty evidence) and intradialytic cramps (10 studies, 14,559 HD sessions: RR 1.84, 95% 1.29 to 2.64; moderate certainty evidence). Effect size for important outcomes were generally greater with low dialysate [Na+] compared to high compared with neutral dialysate [Na+], although formal hypothesis testing identifies that the difference was only certain for postdialysis serum [Na+]. Compared to neutral or high dialysate [Na+], it is uncertain whether low dialysate [Na+] affects intradialytic or interdialytic MAP, and dietary salt intake. It is also uncertain whether low dialysate [Na+] changed extracellular fluid status, venous tone, arterial vascular resistance, left ventricular volumes, or fatigue. Studies did not examine CV or all‐cause death, CV events, or hospitalisation. Low dialysate [Na+] reduces intradialytic weight gain and probably blood pressure, which are effects directionally associated with improved outcomes. However, the intervention probably increases intradialytic hypotension and probably reduces serum [Na+], effects that are associated with an increased risk of death. The effect of the intervention on overall patient health and well‐being is unknown. Further evidence is needed in the form of longer‐term studies in contemporary settings, evaluating end‐organ effects in small‐scale mechanistic studies using optimal methods, and clinical outcomes in large‐scale -Abstract Truncated-

#861 Intradialytic oxygen saturation in chronic hemodialysis patients—results from a large U.S. population

Intra-dialytic blood oxygen saturation (SO2): association with dialysis hypotension (the SOGLIA Study)

Factors responsible for cerebral hypoxia in hemodialysis population

Effect of Dialysate and Plasma Sodium on Mortality in a Global Historical Hemodialysis Cohort

Serum Concentration of Indoxyl Sulfate in Peritoneal Dialysis Patients and Low-Flux Hemodialysis Patients

#4580 ELEVATED LEVELS OF UREMIC SOLUTES IN THE CEREBROSPINAL FLUID OF HEMODIALYSIS PATIENTS

Pulse oximetry monitoring outside the intensive care unit: progress or problem?

#4261 RELATIONSHIP BETWEEN FLUID OVERLOAD AND AVERAGE PLASMA REFILL RATE IN HEMODIALYSIS PATIENTS

Serum Level of Hydrogen Sulfide and Its Influential Factors in Patients Undergoing Maintenance Hemodialysis

Increased Mortality Associated with Higher Pre-Dialysis Serum Sodium Variability: Results of the International MONitoring Dialysis Outcome Initiative

Chronic Therapy with Sucroferric Oxyhydroxide Does Not Affect Iron and Anemia Markers in Dialysis Patients

The oxygen cascade in patients treated with hemodialysis and native high-altitude dwellers: lessons from extreme physiology to benefit patients with end-stage renal disease

Detection of microcirculatory impairment by transcutaneous oxymetry monitoring during hemodialysis: an observational study

Relationship Between Measured and Prescribed Dialysate Sodium in Haemodialysis: a Systematic Review and Meta-Analysis

Serum Phosphorus and Pill Burden Among Hemodialysis Patients Prescribed Sucroferric Oxyhydroxide: One-Year Follow-Up on a Contemporary Cohort

Hemodialysis Use and Practice Patterns: an International Survey Study.

Low dialysate sodium levels for chronic haemodialysis

High facility-level serum potassium variability associated with mortality in hemodialysis patients: results from Chinese Dialysis Outcomes and Practice Patterns Study (DOPPS)

Associations of abnormal fluid status, plasma sodium disorders, and low dialysate sodium with mortality in hemodialysis patients

Changes of Dissociative Properties of Hemoglobin in Patients with Chronic Kidney Disease

Pilot study to investigate differences in middle molecules, oxidative stress and markers of peripheral vascular disease in patients treated by high flux haemodialysis and haemodiafiltration